摘要
目的探讨三甲医院碳青霉烯类药物用药合理性情况。方法回顾性分析内蒙古科技大学包头医学院第一附属医院2018年9月至2019年2月使用美罗培南、亚胺培南西司他丁、厄他培南的全部出院患者469份病历,并按照国家卫健委于2018年9月18日印发的《碳青霉烯类抗菌药物临床应用评价细则》(国卫办医函〔2018〕822号附件2)及相关指南等,评价用药合理性。结果469例患者中,用药前微生物送检率81.88%,根据"评价细则"的评分标准扣分,用药合理性总体评价平均得分87.65分。结论某院碳青霉烯类抗菌药物的临床应用基本合理,仍需进一步提高临床应用水平。
Objective To explore the rationality of the management and clinical application of carbapenem antibiotics in three-A level hospital.Methods A retrospective analysis of 469 medical records was made in all discharged patients with meropenem,imipenem,cilastatin and ertapenem in the First Affiliated Hospital,Baotou Medical College,Inner Mongolia University of Science and Technology,from September 2018 to February 2019.In accordance with the Detailed Evaluation Rules for the Clinical Application of Carbapenem Antibacterials(National Health Office Medical Letter[2018]No.822 Annex 2)and related guidelines issued by the National Health Commission on September 18,2018,the drug is evaluated for reasonable use.Results Among the 469 cases,the pre-medicine microbiological examination rate was 81.88%.According to the scoring standards of"detailed evaluation rules",the average score of the rationality of the medication was 87.65 points.Conclusion The clinical application of carbapenem antibiotics in a hospital is basically reasonable,and it is still necessary tofurther improve the clinical application level.
作者
陈晨
董志强
CHEN Chen;DONG Zhi-Qiang(Clinical Pharmacy,First Affiliated Hospital,Bantou Medical College,Inner Mongolia University of Science and Technology)
出处
《中国药物经济学》
2020年第3期112-115,119,共5页
China Journal of Pharmaceutical Economics
